Spiros D. Ladas

Spiros D. Ladas

Auto-generated profile, based on publicly available information

Spiros D. Ladas

2nd Department of Internal Medicine, Athens University, Evangelismos Hospital, Greece

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SLSpiros D. Ladas
Spiros D. Ladas
Konstantinos TriantafyllouKonstantinos Triantafyllou
Konstantinos Triantafyllou
CTCharalabos Tzathas
Charalabos Tzathas
PTPericles Tassios
Pericles Tassios
TRTheodore Rokkas
Theodore Rokkas
SRSotirios A. Raptis
Sotirios A. Raptis
Large gastric phytobezoars may occur in patients with gastric dysmotility disorders. Treatment options include dissolution with enzymes, endoscopic fragmentation with removal or aspiration, and surgery. We report our experience with nasogastric cola lavage therapy. Over an 8-year period, five consecutive patients were referred to our unit for endoscopic treatment of large gastric phytobezoars. They included one patient with lobectomy for lung cancer and four patients with diabetic gastroparesis. An initial attempt of endoscopic fragmentation and removal was unsuccessful. Patients were treated with 3 l of Coca-Cola nasogastric lavage over 12 h. Nasogastric lavage was very well tolerated by the patients. Complete phytobezoar dissolution was achieved in one session in all cases. There were no procedure-related complications. The dissolution of large gastric phytobezoars with cola nasogastric lavage is a safe, rapid and effective method. Patients may be treated in the medical ward, avoiding therapeutic endoscopy or surgery.

1 January 2006 in Digestion
Verified
Journal Article
Closed access
SLS.D. Ladas
S.D. Ladas
LAL. Aabakken
L. Aabakken
JRJ.-F. Rey
J.-F. Rey
ANA. Nowak
A. Nowak
SZS. Zakaria
S. Zakaria
MZM. Zavoral
M. Zavoral
Background/Aims: Sedation rates may vary among countries, depending on patients’ and endoscopists’ preferences. The aim of this survey was to investigate the rate of using premedication for routine diagnostic upper gastrointestinal (UGI) endoscopy in endoscopy societies, members of the European Society of Gastrointestinal Endoscopy (ESGE). Methods: We evaluated a multiple-choice questionnaire which was e-mailed to representatives of national endoscopy societies, which are members of the ESGE. The questionnaire had 14 items referring to endoscopy practices in each country and the representatives’ endoscopy units. Results: The response rate was 76% (34/45). In 47% of the countries, less than 25% of patients undergo routine diagnostic UGI endoscopy with conscious sedation. In 62% of the responders’ endoscopy units, patients are not asked their preference for sedation and do not sign a consent form (59%). Common sedatives in use are midazolam (82%), diazepam (38%) or propofol (47%). Monitoring equipment is not available ‘in most of the endoscopy units’ in 46% (13/28) of the countries. Though they were available in 91% of the national representatives’ endoscopy units, they are rarely (21%) used to monitor unsedated routine diagnostic UGI endoscopy. Conclusions: In about 50% of ESGE-related countries, less than 25% of patients are sedated for routine diagnostic UGI endoscopy. Major issues to improve include availability of monitoring equipment and the use of a consent form.

4 March 2002 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
SGS. D. Georgopoulos
S. D. Georgopoulos
SLS. D. Ladas
S. D. Ladas
SKS. Karatapanis
S. Karatapanis
Konstantinos TriantafyllouKonstantinos Triantafyllou
Konstantinos Triantafyllou
CSC. Spiliadi
C. Spiliadi
SRS. A. Raptis
S. A. Raptis
Background: There are no guidelines on second‐line therapies for Helicobacter pylori eradication failures of omeprazole–clarithromycin–amoxicillin triple therapy.Aim: To compare the efficacy of two second‐line therapies for persistent H. pylori infection.Methods: Over a 6‐year period, patients with persistent H. pylori infection following omeprazole–clarithromycin–amoxicillin eradication therapy were randomized to receive omeprazole, 20 mg twice daily, bismuth, 120 mg four times daily, metronidazole, 500 mg twice daily, and either tetracycline, 500 mg four times daily, or clarithromycin, 500 mg twice daily, given for 7 days. Before therapy, patients underwent endoscopy with biopsies for histology, culture and antibiotic susceptibility tests. H. pylori infection was confirmed by histology.Results: Of the 95 randomized patients, 88 (93%) completed the study. Age, sex, smoking, ulcer/non‐ulcer dyspepsia ratio and antibiotic resistance were not significantly different between the treatment groups. On intention‐to‐treat analysis, eradication was achieved in 41 of the 49 patients (84%; 95% confidence interval, 70.4–92.7%) and 27 of the 46 patients (59%; 95% confidence interval, 43.3–73.0%) of the tetracycline‐ and clarithromycin‐containing groups, respectively (P=0.007). On multivariate regression analysis, the sensitivity of H. pylori to metronidazole had a likelihood ratio of 5.2 (P=0.022), followed by the type of quadruple therapy (likelihood ratio, 4.4; P=0.036).Conclusions: Tetracycline‐containing quadruple rescue therapy is highly effective in treating H. pylori eradication failures of the omeprazole–amoxicillin–clarithromycin regimen.

1 January 2007 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
CKChryssostomos Kalantzis
Chryssostomos Kalantzis
Konstantinos TriantafyllouKonstantinos Triantafyllou
Konstantinos Triantafyllou
APAngelos A. Papadopoulos
Angelos A. Papadopoulos
GAGeorge Alexandrakis
George Alexandrakis
TRTheodore Rokkas
Theodore Rokkas
SLSpiros D. Ladas
Spiros D. Ladas
Objective. Video capsule endoscopy fails to visualize the caecum in about 20% of patients. The aim of this study was to investigate the effect of different bowel preparations on video capsule endoscopy gastric- (GTT) and small-bowel transit time (SBTT) and the rate of caecal visualization. Material and methods. We retrospectively examined 186 consecutive capsule endoscopy videos undertaken over a 3-year period, excluding cases with diabetes mellitus or gastric surgery (n=28), cases with unknown bowel preparation and those with unreadable data CDs (n=27). Sixty-seven (36%) patients were prepared with a liquid diet (CL), 54 (29%) with sodium phosphate (PS) and 65 (35%) with polyethylene glycol (PEG). Two independent, experienced investigators examined the videos. Results. No difference was found in GTT among CL, PS and PEG preparations (25, 6.7–116.2 min, 34.75, 4.1–125 min, 35, 6.1–128.6 min, respectively, p=0.29). The caecum was visualized in 56/67 (83.6%), 44/54 (81.5%) and 53/65 (81.5%) patients who received CL, PS and PEG, respectively (p=0.9). In the cases where capsule endoscopy reached the caecum, no difference was observed in SBTT among patients that received CL, PS and PEG (264.4±85.9 min, 296.7±79.5 min, 291.3±84 min, respectively, p=0.11). Conclusions. Bowel preparations for capsule endoscopy do not have a significant effect on gastric and small-bowel video capsule transit time and the rate of caecum visualization.

1 November 1998 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SLSpiros D. Ladas
Spiros D. Ladas
EVEmmanuel Vaidakis
Emmanuel Vaidakis
CLConstantina Lariou
Constantina Lariou
KAKonstantinos Anastasiou
Konstantinos Anastasiou
GCGeorgios Chalevelakis
Georgios Chalevelakis
SRSotirios A. Raptis
Sotirios A. Raptis
We present two cases of biopsy proven tuberculosis of the pancreas in non-immunocompromised patients diagnosed and treated in our unit within the last 14 years. The first case presented with abdominal pain and fever, and the second with iron deficiency anaemia and severe weight loss. In both cases abdominal ultrasound and computed tomography suggested a pancreatic carcinoma. There was no pulmonary or intestinal tuberculosis. The tuberculin skin test was positive. Upon exploratory laparotomy the macroscopic appearance of the pancreas was that of an inoperable pancreatic carcinoma. Following the histological diagnosis of pancreatic tuberculosis, both patients were successfully treated with triple antituberculous therapy for 6 months. Isolated pancreatic tuberculosis is an extremely rare disease with only 41 cases in non-immunocompromised patients reported worldwide (1966-1997). It is a curable disease and should be considered in the differential diagnosis of a pancreatic mass or abscess shown on ultrasound or computed tomography, especially in developing countries, where tuberculosis is common.

11 November 2005 in Gut
Verified
Journal Article
Open access
PDF file
APA A Papadopoulos
A A Papadopoulos
CTC Tzathas
C Tzathas
DPD Polymeros
D Polymeros
SLS D Ladas
S D Ladas
A 44 year old woman presented with a two month history of vomiting, nausea, and crampy abdominal pain. Her past medical history included idiopathic thrombocytopenic purpura, splenectomy at the age of 11 years, hyperlipidaemia, hypertension, diabetes mellitus type II, and depression. Her medication included valsartan, atenolol, nifedipine, gliclazide, metformin hydrochloride, indapamide, and venlafaxine hydrochloride. No food allergy or intolerance was reported.